Spyre Therapeutics Commences $300M Public Offering

Spyre Therapeutics, a clinical-stage biotechnology company, announced the commencement of an underwritten public offering of $300.0 million of its common stock. The company will sell all shares in the offering, and underwriters have an option to purchase an additional $45.0 million in shares. This capital raise is intended to fund the company's ongoing development in inflammatory bowel disease and other immune-mediated diseases, but it may lead to dilution for existing shareholders.